CYP3A4/5 polymorphisms affect the blood level of cyclosporine and tacrolimus in Chinese renal transplant recipients.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  International journal of clinical pharmacology and therapeutics

• Publication date

  2013-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.5414/CP201836PMID 23557867
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci

  2023cited by this paper
• Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients

  2011cited by this paper
• Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis

  2011cited by this paper
• A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis (http://analysis.bio-x.cn)

  2009cited by this paper
• Cyclosporine C2 levels have impact on incidence of rejection in de novo lung but not heart transplant recipients: the NOCTURNE study.

  2009cited by this paper
• Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem‐cell transplant recipients. The trough level is not enough

  2009cited by this paper
• Effect of bifendate on the pharmacokinetics of cyclosporine in relation to the CYP3A4*18B genotype in healthy subjects

  2009cited by this paper
• Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.

  2008cited by this paper
• CYP3A7, CYP3A5, CYP3A4, and ABCB1 Genetic Polymorphisms, Cyclosporine Concentration, and Dose Requirement in Transplant Recipients

  2008cited by this paper
• Association of MDR1, CYP3A4*18B, and CYP3A5*3 polymorphisms with cyclosporine pharmacokinetics in Chinese renal transplant recipients

  2008cited by this paper
• Role of Pharmacogenetics of Immunosuppressive Drugs in Organ Transplantation

  2008cited by this paper
• Impact of CYP3A5 genetic polymorphism on pharmacokinetics of tacrolimus in healthy Japanese subjects.

  2008cited by this paper
• Association of CYP3A4*18B polymorphisms with the pharmacokinetics of cyclosporine in healthy subjects

  2007cited by this paper
• CYP3A5 Genotype Markedly Influences the Pharmacokinetics of Tacrolimus and Sirolimus in Kidney Transplant Recipients

  2007cited by this paper
• Therapeutic monitoring of calcineurin inhibitors for the nephrologist.

  2007cited by this paper
• Assessment of cyclosporine pharmacokinetic parameters to facilitate conversion from C0 to C2 monitoring in heart transplant recipients.

  2007cited by this paper
• Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients

  2006cited by this paper
• An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients.

  2006cited by this paper
• Cyp3A4, Cyp3A5, and MDR-1 genetic influences on tacrolimus pharmacokinetics in renal transplant recipients

  2006cited by this paper
• Influence of CYP3A5 and MDR1 polymorphisms on tacrolimus concentration in the early stage after renal transplantation

  2005cited by this paper
• AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients.

  2005cited by this paper
• METABOLISM-BASED DRUG-DRUG INTERACTIONS: WHAT DETERMINES INDIVIDUAL VARIABILITY IN CYTOCHROME P450 INDUCTION?

  2005cited by this paper
• C2 is superior to C0 as predictor of renal toxicity and rejection risk profile in stable heart transplant recipients

  2005cited by this paper
• Pharmacokinetic Principles of Immunosuppressive Drugs

  2005cited by this paper
• CYP3A5 Polymorphism and the Ethnic Differences in Cyclosporine Pharmacokinetics in Healthy Subjects 1

  2004cited by this paper
• The Effect of CYP3A5 and MDR1 Polymorphic Expression on Cyclosporine Oral Disposition in Renal Transplant Patients

  2003cited by this paper
• Genetic contribution to variable human CYP3A-mediated metabolism.

  2002cited by this paper
• Improved graft survival after renal transplantation in the United States, 1988 to 1996.

  2000cited by this paper

• Calcineurin Inhibitor Associated Nephrotoxicity in Kidney Transplantation—A Transplant Nephrologist's Perspective

  2025cites this paper
• Genetic Modulation of Silodosin Exposure and Efficacy: The Role of CYP3A4, CYP3A5, and UGT2B7 Polymorphisms in Benign Prostatic Hyperplasia Management

  2025cites this paper
• The effect of CYP3A4, CYP3A5 and MDR1 (ABCB1) single nucleotide polymorphisms on the pharmacokinetics of cyclosporine in Algerian stable renal transplant recipients

  2025cites this paper
• A comparative analysis of drug-induced kidney injury adverse reactions between cyclosporine and tacrolimus based on the FAERS database

  2025influential citation
• [Pharmacogenetic testing improves treatment responses in patients with PLA2R-related membranous nephropathy].

  2023cites this paper
• Reaching the cyclosporine a level target slowly in four weeks correlates with better prognosis for Chinese patients after allogeneic haematopoietic cell transplantation

  2023cites this paper
• Association of high intra-patient variability in tacrolimus exposure with calcineurin inhibitor nephrotoxicity in kidney transplantation

  2023cites this paper
• Pharmacogenomics of Old and New Immunosuppressive Drugs for Precision Medicine in Kidney Transplantation

  2023influential citation
• The Effect of Voriconazole on Tacrolimus in Kidney Transplantation Recipients: A Real-World Study

  2022cites this paper
• Use of Pharmacogenetics to Optimize Immunosuppressant Therapy in Kidney-Transplanted Patients

  2022cites this paper
• Worsening of Kidney Transplant Function During 2-Year Follow-up Is Associated With the Genetic Variants of CYP3A4, MDR1, and UGT1A9.

  2020cites this paper
• Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives

  2020cites this paper
• Significance of ethnic factors in immunosuppressive therapy management after organ transplantation.

  2020cites this paper
• The influence of CYP3A4 and CYP3A5 gene polymorphism on individualized medication of FK506 and hepatorenal function after liver transplantation

  2019cites this paper
• Association of genetic variants in CYP3A4, CYP3A5, CYP2C8, and CYP2C19 with tacrolimus pharmacokinetics in renal transplant recipients.

  2019cites this paper
• Biomarkers and Pharmacogenomics in Kidney Transplantation

  2018cites this paper
• Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.

  2018cites this paper
• Caveolin-1 in renal disease

  2018influential citation
• Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients.

  2017cites this paper
• Effect of CYP3A4∗1G and CYP3A5∗3 Polymorphisms on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Healthy Chinese Subjects

  2017cites this paper
• Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement

  2017cites this paper
• Association between the CYP 3 A 4 * 18 B polymorphism and pharmacokinetics of cyclosporine-A in recipients of kidney transplantation in Chinese patients : a meta-analysis of observational studies

  2016cites this paper
• External evaluation of published population pharmacokinetic models of tacrolimus in adult renal transplant recipients.

  2016cites this paper
• Economic Evaluation of Pharmacogenetic Tests in Patients Subjected to Renal Transplantation: A Review of Literature

  2016cites this paper
• Increased Tacrolimus Levels After Administration of Ciprofloxacin to a Patient with Renal Transplant

  2016cites this paper
• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing

  2015cites this paper
• The effect of CYP3A5 polymorphism on cyclosporine plasma level in Egyptian renal transplant recipients

  2015cites this paper
• Tacrolimus in preventing transplant rejection in Chinese patients – optimizing use

  2015cites this paper
• An Open-Label Investigation into Drug–Drug Interactions Between Multiple Doses of Daclatasvir and Single-Dose Cyclosporine or Tacrolimus in Healthy Subjects

  2015influential citation
• Etude rétrospective de l'influence des polymorphismes génétiques de CYP3A4, CYP3A5 et ABCB1 des donneurs et des receveurs sur les effets des immunosuppresseurs en transplantation hépatique

  2015influential citation
• Pharmacogenetics and drug-induced nephrotoxicity in renal transplant recipients

  2015cites this paper
• Effect of CYP3A5 gene polymorphisms on tacrolimus concentration/dosage ratio in adult liver transplant patients.

  2015influential citation
• Genetic polymorphisms and kidney transplant outcomes

  2014cites this paper
• Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

  2014cites this paper
• Pharmacogenetics and immunosuppressive drugs

  2014influential citation
• Homogeneous phenomenon of the graft when using different genotype characteristic of recipients/donors in living donor liver transplantation.

  2013cites this paper
• Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.

  2013cites this paper